GleamWall
中文EN

GILD GILEAD SCIENCES, INC.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 882095 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY6.5%
TTM net income YoY-147.6%
TTM EPS YoY-148.5%
Revenue 3-yr CAGR4.2%
Net income 3-yr CAGR—

Margins

Gross margin79.9%
Operating margin-7.6%
Net margin-12.5%
FCF margin44.5%
EBITDA margin-6.3%

Returns

ROE-22.3%
ROA-7.0%
ROIC (approx.)-5.2%
Asset turnover0.56x

Leverage & solvency

Liabilities / assets74.8%
Debt / equity2.01x
Current ratio1.38x
Interest coverage-2.34x

Cash quality & payout

Operating cash flow / net income-3.75x
Accruals ratio-33.4%
Payout ratio—
Capex / revenue2.3%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$29.44B$28.75B
Cost of revenue$6.23B$6.25B
Gross profit$23.21B$22.50B
R&D expense$5.80B$5.91B
SG&A expense$5.77B$6.09B
Operating income$10.02B$1.66B
Interest expense$1.02B$977.00M
Pretax income$9.80B$690.00M
Income tax$1.29B$211.00M
Net income$8.51B$480.00M
EBITDA$10.39B$2.04B
EPS (basic)6.840.38
EPS (diluted)6.780.38
Dividends declared per share3.163.08
Weighted avg. shares (diluted)1.25B1.25B
Balance sheet
Cash & equivalents$7.56B$9.99B
Short-term investments$68.00M$0
Receivables$4.91B$4.42B
Inventory$1.77B$1.71B
Current assets$18.34B$19.17B
PP&E, net$5.61B$5.41B
Goodwill$8.31B$8.31B
Intangibles$16.98B$19.95B
Total assets$59.02B$58.99B
Current liabilities$11.81B$12.00B
Short-term debt$2.81B$1.81B
Long-term debt$22.13B$24.90B
Total debt$24.94B$26.71B
Total liabilities$36.41B$39.75B
Shareholders' equity$22.70B$19.33B
Net debt$17.37B$16.72B
Shares outstanding1.24B1.25B
Cash flow statement
Operating cash flow$10.02B$10.83B
Capital expenditure$563.00M$523.00M
Free cash flow$9.46B$10.30B
Investing cash flow-$4.79B-$3.45B
Financing cash flow-$7.75B-$3.43B
Depreciation & amortization$370.00M$381.00M
Stock-based compensation$894.00M$835.00M
Dividends paid$4.00B$3.92B
Share buybacks$1.92B$1.15B

Free plan shows the latest 2 periods; Pro shows all 19 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.